WO1998043641A1 - Composition pharmaceutique, cosmetique et/ou alimentaire aux proprietes anti-oxydantes - Google Patents
Composition pharmaceutique, cosmetique et/ou alimentaire aux proprietes anti-oxydantes Download PDFInfo
- Publication number
- WO1998043641A1 WO1998043641A1 PCT/BE1998/000044 BE9800044W WO9843641A1 WO 1998043641 A1 WO1998043641 A1 WO 1998043641A1 BE 9800044 W BE9800044 W BE 9800044W WO 9843641 A1 WO9843641 A1 WO 9843641A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical
- cosmetic
- alkylaryl
- arylalkyl
- food composition
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 33
- 235000013305 food Nutrition 0.000 title claims abstract description 30
- 239000002537 cosmetic Substances 0.000 title claims abstract description 29
- 230000003078 antioxidant effect Effects 0.000 title description 6
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 12
- 230000007170 pathology Effects 0.000 claims abstract description 12
- 125000002877 alkyl aryl group Chemical group 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 8
- 125000005842 heteroatom Chemical group 0.000 claims abstract description 8
- 150000003216 pyrazines Chemical class 0.000 claims abstract description 7
- 125000003342 alkenyl group Chemical group 0.000 claims abstract description 6
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 6
- 125000004404 heteroalkyl group Chemical group 0.000 claims abstract description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 6
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 5
- 125000000304 alkynyl group Chemical group 0.000 claims abstract description 5
- 125000003118 aryl group Chemical group 0.000 claims abstract description 5
- 230000002265 prevention Effects 0.000 claims description 13
- 230000009471 action Effects 0.000 claims description 12
- 239000007800 oxidant agent Substances 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 8
- 201000001320 Atherosclerosis Diseases 0.000 claims description 6
- 230000002757 inflammatory effect Effects 0.000 claims description 4
- 230000003244 pro-oxidative effect Effects 0.000 claims description 4
- 230000000711 cancerogenic effect Effects 0.000 claims description 2
- 231100000315 carcinogenic Toxicity 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 abstract description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 4
- 239000001301 oxygen Substances 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 3
- 125000005025 alkynylaryl group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- BWNPYAKFDUFNND-UHFFFAOYSA-N coelenteramine Natural products NC1=NC=C(C=2C=CC(O)=CC=2)N=C1CC1=CC=CC=C1 BWNPYAKFDUFNND-UHFFFAOYSA-N 0.000 description 26
- XMGXGGJFFSGNJK-UHFFFAOYSA-N coelenteramine Chemical compound N1C(=C2C=CC(=O)C=C2)C=NC(N)=C1CC1=CC=CC=C1 XMGXGGJFFSGNJK-UHFFFAOYSA-N 0.000 description 26
- 102000007330 LDL Lipoproteins Human genes 0.000 description 22
- 108010007622 LDL Lipoproteins Proteins 0.000 description 22
- 230000003647 oxidation Effects 0.000 description 14
- 238000007254 oxidation reaction Methods 0.000 description 14
- CIHOLLKRGTVIJN-UHFFFAOYSA-N tert‐butyl hydroperoxide Chemical compound CC(C)(C)OO CIHOLLKRGTVIJN-UHFFFAOYSA-N 0.000 description 14
- 210000003494 hepatocyte Anatomy 0.000 description 10
- 239000003981 vehicle Substances 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000003963 antioxidant agent Substances 0.000 description 7
- 150000001993 dienes Chemical class 0.000 description 7
- 230000004083 survival effect Effects 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
- LXEKPEMOWBOYRF-QDBORUFSSA-N AAPH Chemical compound Cl.Cl.NC(=N)C(C)(C)\N=N\C(C)(C)C(N)=N LXEKPEMOWBOYRF-QDBORUFSSA-N 0.000 description 6
- 235000006708 antioxidants Nutrition 0.000 description 6
- 239000010949 copper Substances 0.000 description 6
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 5
- 229910052802 copper Inorganic materials 0.000 description 5
- 150000002632 lipids Chemical class 0.000 description 5
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 5
- 229960000564 nitrofurantoin Drugs 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 3
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 125000004432 carbon atom Chemical group C* 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- YHIPILPTUVMWQT-UHFFFAOYSA-N Oplophorus luciferin Chemical compound C1=CC(O)=CC=C1CC(C(N1C=C(N2)C=3C=CC(O)=CC=3)=O)=NC1=C2CC1=CC=CC=C1 YHIPILPTUVMWQT-UHFFFAOYSA-N 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical class C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- 239000000524 Thiobarbituric Acid Reactive Substance Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 229910052785 arsenic Inorganic materials 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 229910052714 tellurium Inorganic materials 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N (R)-alpha-Tocopherol Natural products OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- ZKAMEFMDQNTDFK-UHFFFAOYSA-N 1h-imidazo[4,5-b]pyrazine Chemical class C1=CN=C2NC=NC2=N1 ZKAMEFMDQNTDFK-UHFFFAOYSA-N 0.000 description 1
- CCTFAOUOYLVUFG-UHFFFAOYSA-N 2-(1-amino-1-imino-2-methylpropan-2-yl)azo-2-methylpropanimidamide Chemical compound NC(=N)C(C)(C)N=NC(C)(C)C(N)=N CCTFAOUOYLVUFG-UHFFFAOYSA-N 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 1
- 229910021592 Copper(II) chloride Inorganic materials 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical class [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000000923 atherogenic effect Effects 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000009704 beneficial physiological effect Effects 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 235000017471 coenzyme Q10 Nutrition 0.000 description 1
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 150000001944 cysteine derivatives Chemical class 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- -1 superoxide anions Chemical class 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- AOBORMOPSGHCAX-DGHZZKTQSA-N tocofersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2O[C@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-DGHZZKTQSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention relates to a pharmaceutical, cosmetic and / or food composition intended in particular for the prevention and / or treatment of pathologies linked to pro-oxidant agents.
- the present invention also relates to the use of the pharmaceutical, cosmetic and / or food composition according to the invention.
- Patent application O96 / 28160 describes a pharmaceutical, cosmetic and / or food composition having antioxidant properties, and comprising a pyrazine derivative or a precursor thereof, the derivatives being imidazolopyrazines such as coelenterazine.
- This document also describes the use of such a pharmaceutical, cosmetic and / or food composition for the treatment of pathologies linked to the action of pro-oxidizing agents such as inflammatory pathologies, or the application of said composition for the treatment of cancerous tumors.
- Antioxidant molecules such as vitamins such as vitamin E (soluble in lipids) or cysteine derivatives (soluble in water) are also already used in cosmetic, pharmaceutical and / or food applications. However, such antioxidant molecules are characterized either by a low solubility in water, or by a high toxicity, by a too low efficiency or by a low stability with respect to oxygen.
- the present invention aims to obtain a pharmaceutical, cosmetic and / or food composition allowing the fixation of pro-oxidizing agents which would not have the drawbacks of the state of the art.
- a particular aim of the present invention is to obtain a pharmaceutical, cosmetic and / or food composition advantageously allowing the prevention and / or the treatment of pathologies linked to prooxidants.
- Another object of the present invention is to provide a pharmaceutical, cosmetic and / or food composition which is characterized by improved stability compared to the products of the state of the art, by low toxicity or absence of toxicity, by a high solubility in a large number of solvents and / or lipids. Characteristic elements of the present invention
- the present invention relates to a pharmaceutical, cosmetic and / or food composition
- a pharmaceutical, cosmetic and / or food composition comprising a pyrazine derivative of formula
- radicals R 1 to R 9 are H, radicals chosen from the group consisting of alkyl, alkenyl, alkynyl, aryl, arylalkyl, alkylaryl, heteroaryl, heteroalkyl and hetero (alkylaryl and arylalkyl), preferably consisting of 1 to 20 carbon atoms optionally comprising 1 to 10 heteroatoms and whose carbon atoms may be optionally substituted by any element from the Mendeleev table, preferably an element chosen from the group consisting of H, B, N, O, F, P , S, Cl, As, Se, Br, Te and I, or chains of formula (R 5 x R 6 ) n , where n> 1, x represents one or more hetero atoms and R ⁇ and R ⁇ are radicals chosen from the group consisting of alkyl, alkenyl, alkynyl, aryl, arylalkyl, alkylaryl, heteroaryl, heteroalkyl and hetero (alkylaryl
- the radicals R 2 to R 9 are H and the radical R 1 is a radical of formula C ⁇ - ⁇ O / and optionally a suitable pharmaceutical, cosmetic and / or food vehicle .
- composition according to the invention for fixing pro-oxidizing agents (activated forms of oxygen) such as peroxides, superoxides, etc.
- the present invention also relates to a process for fixing pro-oxidizing agents in which the pharmaceutical, cosmetic and / or food composition is brought into contact with said pro-oxidizing agents.
- the present invention also relates to a method of treatment and / or prevention of pathologies linked to the action of pro-oxidizing agents, in particular inflammatory pathologies, as well as a method of treatment and / or prevention of atherosclerosis , in which the pharmaceutical, cosmetic and / or food composition according to the present invention is administered to a patient (human or animal).
- the pharmaceutical, cosmetic and / or food composition is associated with a therapeutic effect.
- said composition can also be characterized as being a "functional" food composition.
- a “functional food composition” is characterized in that it comprises one or more ingredients capable of having a beneficial physiological effect on the consumer, such as the prevention of disease, treatment of a disease, activation of biorhythm or immune system.
- a functional food composition may be included in the normal diet of the consumer, so as to provide a general improvement in the health of the patient or to obtain the treatment or prevention of a particular disease, provided that said functional food composition has a significant effect both from a preventive and therapeutic point of view on the consumer.
- Said pharmaceutical, cosmetic and / or food composition will comprise a sufficient amount of the pyrazine derivative according to the invention so as to obtain a prevention or a significant therapeutic effect on the consumer.
- the proportion of the pyrazine derivative according to the invention in the pharmaceutical, cosmetic and / or food composition according to the invention will vary as a function of the daily amounts of product absorbed, according to the appropriate food, cosmetic and pharmaceutical legislation, the organoleptic assessments and the effects secondary likely to exist with the derivatives according to the invention and / or their pharmaceutical, cosmetic and / or food vehicles used.
- the pharmaceutical, cosmetic and / or food vehicles of the compositions according to the invention are suitable vehicles in particular for oral administration, for example in the form of tablets, coated or uncoated, pills, capsules, solutions, oils essentials and / or syrups.
- these pharmaceutical, cosmetic and / or food vehicles can be sunscreen creams or oils well known to those skilled in the art, which can coat different parts of the human or animal body in combination with other protective agents for the skin. .
- the products of the invention can be easily incorporated into solvents (aqueous media, alcohols, etc.) or lipids (for example in combination with edible oils or tanning oils).
- compositions according to the invention are prepared according to methods generally used by those skilled in the art, in particular by pharmacists, and can comprise any pharmaceutically suitable vehicle or adjuvant, solid or liquid, and not toxic.
- the incorporation of the derivatives according to the invention in a galenical medium can also be envisaged.
- the percentage of active product (pyrazine derivatives) in the pharmaceutical, cosmetic and / or food vehicle can vary according to very wide ranges, generally limited by the tolerance and the level of acceptance of the composition by the consumer. The limits are generally determined by the frequency of consumption of the composition by the consumer.
- a final aspect of the present invention relates to the use of the composition according to the invention for the preparation of a medicament intended for the prevention and / or treatment of pathologies linked to the action of pro-oxidizing agents.
- the present invention relates to the use of the composition according to the invention for the preparation of a medicament intended for the prevention and / or treatment of inflammatory or carcinogenic pathologies, for the prevention of atherosclerosis and / or for treatment of cancerous tumors.
- FIG. 1 represents the percentage cell survival of rat hepatocytes as a function of increasing doses (molars) of coelenteramine.
- FIG. 2 represents the oxidation of "low-density lipoproteins" (LDL) with a water-soluble root initiator (AAPH) in the presence of coelenteramine.
- FIG. 3 represents the monitoring of the oxidation of human "low-density lipoproteins" with Cu 2 + as a function of time.
- FIG. 4 illustrates the percentage of survival of hepatocytes subjected to the action of nitrofurantoin.
- FIG. 1 represents the percentage cell survival of rat hepatocytes as a function of increasing doses (molars) of coelenteramine.
- FIG. 2 represents the oxidation of "low-density lipoproteins" (LDL) with a water-soluble root initiator (AAPH) in the presence of coelenteramine.
- FIG. 3 represents the monitoring of the oxidation of
- FIG. 5 illustrates the increase in the resistance of fibroblasts subjected to the action of oxidative stress (increasing concentration of t-BHP) in the presence or in the absence of coelenteramine.
- FIG. 6 illustrates the reduction in the release of lactate dehydrogenase by rat hepatocytes when increasing doses of coelenteramine are added to the culture medium. Examples
- Coelenteramine is a natural product found in marine organisms, which is derived from the oxidation of coelentrazine.
- the structure of coelenteramine is illustrated below. This structure has the following characteristics:
- Example 1 Stability Coelenteramine is characterized by excellent oxygen stability, both in powder form and after solubilization in aqueous and organic solvents. Indeed, this molecule is not altered by a stay of several days in aqueous solvent exposed to air. After several days, no degradation product of coelenteramine was identified after chromatographic analysis in HPLC and TLC.
- Example 2 Toxicity Coelenteramine is characterized by an absence of toxicity both on hepatic cells and on intestinal cells or fibroblasts.
- Coelenteramine was applied to primary cultures of rat hepatocytes seeded in microplates (20,000 cells per well, 200 ⁇ l). The doses in CLM ranged from 1.3 ⁇ 10 -5 to 5 ⁇ 10 -4 M. After a period of 24 hours, their survival was evaluated by measuring the total protein content in each well (Bradford method). The results, represented in FIG. 1, expressed as a percentage of the survival of the controls not treated with CLM, demonstrate that the latter is not at all toxic for hepatocytes at these concentrations. of the Similar results were obtained on human fibroblasts (MRC-5) as well as human intestinal cells (CAC02).
- LDL low-density lipoproteins
- vitamin C ubiquinone
- ⁇ -carotene represent the other main antioxidant molecules of LDL. It has been demonstrated in vitro that the transformation of macrophages into foam-charged lipid cells (which are the main constituents of atherosclerotic plaque) is linked to a change in the oxidative nature of LDL.
- the oxidation of LDL is a process mediated by free radicals and initiated by the peroxidation of polyunsaturated fatty acids after consumption of antioxidants.
- the oxidation of LDL greatly increases the atherogenic properties.
- Epidemiological studies have shown an inverse relationship between cardiovascular mortality and the plasma concentration of antioxidants (such as vitamin E). Consequently, water- and fat-soluble antioxidants can protect LDL and delay or prevent their oxidation process.
- the in vitro oxidation of LDL is compared in the absence or in the presence of variable concentrations of coelenteramine.
- the oxidation of polyunsaturated fatty acids from LDL is accompanied by the formation of conjugated dienes which have a maximum absorbance at 234 nm.
- conjugated dienes result from the rearrangement of the double bonds of polyunsaturated fatty acids following the abstraction of a malonic hydrogen. The increase in the absorption of conjugated dienes can be directly measured in solution without having to use lipid extraction.
- the oxidation of LDL can be catalyzed by metal ions such as copper or triggered by a water-soluble radical initiator such as 2,2'-azobis (2-amidinopropane) (AAPH).
- metal ions such as copper
- AAPH 2,2'-azobis (2-amidinopropane)
- an LDL solution (final concentration of 50 ⁇ g protein / ml of PBS buffer, pH 7.4) is incubated in the presence of 5 ⁇ M of copper or 2 ⁇ M of AAPH and in the absence or in the presence of presence of variable CLM concentrations in a quartz cuvette having an optical path of 1 cm.
- the absorbances at 234 nm of the different samples are measured as a function of time on a UV-visible spectrophotometer (DU-8, Beckman).
- a blank is obtained using an LDL-free phosphate solution but containing 5 ⁇ M CuCl2 • 2H2O and 2.5 ⁇ M CLM.
- the tests are carried out at 30 ° C for the oxidation of LDL in the presence of copper and at 37 ° C in the presence of AAPH.
- FIG. 3 illustrates the delay in the appearance of TBARS (thiobarbituric acid reactive substances), corresponding essentially to malonaldialdehyde (MDA), product of the oxidation of lipids contained in LDL.
- TBARS thiobarbituric acid reactive substances
- MDA malonaldialdehyde
- FIG. 4 illustrates the survival of hepatocytes subjected to the action of NF 3 10 -4 M for 6 hours. At the end of this treatment, the survival (estimated by the MTT method) was 18% in the control groups.
- the survival was 18% in the control groups.
- FIG. 6 illustrates the reduction in the release of lactate dehydrogenase (LDH), indicative of cytotoxicity, by the cells when the CLM (10 and 50 ⁇ M) is added to the culture medium. Mortality, which is 75% in controls, only reaches a few% in the presence of 50 ⁇ M CLM.
- LDH lactate dehydrogenase
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP54100198A JP2001524076A (ja) | 1997-03-28 | 1998-03-30 | 抗酸化性を有する薬品、化粧品、食品用組成物 |
US09/402,099 US6376498B1 (en) | 1997-03-28 | 1998-03-30 | Pharmaceutical, cosmetic and/or food composition with antioxidant properties |
EP98913456A EP0975346A1 (fr) | 1997-03-28 | 1998-03-30 | Composition pharmaceutique, cosmetique et/ou alimentaire aux proprietes anti-oxydantes |
CA002293359A CA2293359A1 (fr) | 1997-03-28 | 1998-03-30 | Composition pharmaceutique, cosmetique et/ou alimentaire aux proprietes anti-oxydantes |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BE9700294A BE1011077A3 (fr) | 1997-03-28 | 1997-03-28 | Composition pharmaceutique, cosmetique et/ou alimentaire aux proprietes anti-oxydantes. |
BE9700294 | 1997-03-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998043641A1 true WO1998043641A1 (fr) | 1998-10-08 |
Family
ID=3890437
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/BE1998/000044 WO1998043641A1 (fr) | 1997-03-28 | 1998-03-30 | Composition pharmaceutique, cosmetique et/ou alimentaire aux proprietes anti-oxydantes |
Country Status (6)
Country | Link |
---|---|
US (1) | US6376498B1 (fr) |
EP (1) | EP0975346A1 (fr) |
JP (1) | JP2001524076A (fr) |
BE (1) | BE1011077A3 (fr) |
CA (1) | CA2293359A1 (fr) |
WO (1) | WO1998043641A1 (fr) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001044206A1 (fr) * | 1999-12-17 | 2001-06-21 | Chiron Corporation | Inhibiteurs a base de pyrazine de glycogene synthase kinase 3 |
WO2001087853A1 (fr) * | 2000-05-17 | 2001-11-22 | Universite Catholique De Louvain | Derives de pyrazine et d'imidazopyrazine comme antioxydants |
US6995161B2 (en) | 2000-02-16 | 2006-02-07 | Neurogen Corporation | Substituted arylpyrazines |
US7015227B2 (en) | 2002-06-21 | 2006-03-21 | Cgi Pharmaceuticals, Inc. | Certain amino-substituted monocycles as kinase modulators |
US7179807B2 (en) | 2002-08-20 | 2007-02-20 | Neurogen Corporation | 5-substituted-2-arylpyrazines |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA200602585B (en) | 2003-09-29 | 2007-08-29 | Heineken Supply Chain Bv | Beverages and foodstuffs resistant to light induced flavour changes, processes for making the same, and compositions for imparting such resistance |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996028160A1 (fr) * | 1995-03-09 | 1996-09-19 | Universite Catholique De Louvain | Composition pharmaceutique, cosmetique et/ou alimentaire aux prorpietes anti-oxydantes |
-
1997
- 1997-03-28 BE BE9700294A patent/BE1011077A3/fr not_active IP Right Cessation
-
1998
- 1998-03-30 WO PCT/BE1998/000044 patent/WO1998043641A1/fr not_active Application Discontinuation
- 1998-03-30 CA CA002293359A patent/CA2293359A1/fr not_active Abandoned
- 1998-03-30 EP EP98913456A patent/EP0975346A1/fr not_active Withdrawn
- 1998-03-30 JP JP54100198A patent/JP2001524076A/ja active Pending
- 1998-03-30 US US09/402,099 patent/US6376498B1/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996028160A1 (fr) * | 1995-03-09 | 1996-09-19 | Universite Catholique De Louvain | Composition pharmaceutique, cosmetique et/ou alimentaire aux prorpietes anti-oxydantes |
Non-Patent Citations (3)
Title |
---|
INOUE ET AL.: "A new synthesis of Watasenia preluciferin by cyclisation of 2-amino-3-benzyl-5-(p-hydroxyphenyl)pyrazine with p-hydroxyphenylpyruvic acid.", CHEM. LETT., vol. 3, 1980, P0C038, pages 299 - 300, XP002045630 * |
LUCAS ET AL.: "Coelenterazine Is a Superoxide Anion-Sensitive Chemiluminescent Probe: Its Usefulness in the Assay of Respiratory Burst in Neutrophils", ANAL. BIOCHEM., vol. 206, 1992, pages 273 - 277, XP002045628 * |
NAKONA M.: "Determination of Superoxide Radical and Singlet Oxygen Based on Chemiluminescence of Luciferin Analogs.", METHODS ENZYMOLOGY, vol. 186, 1990, pages 585 - 592, XP002045627 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001044206A1 (fr) * | 1999-12-17 | 2001-06-21 | Chiron Corporation | Inhibiteurs a base de pyrazine de glycogene synthase kinase 3 |
US6949547B2 (en) | 1999-12-17 | 2005-09-27 | Chiron Corporation | Pyrazine based inhibitors of glycogen synthase kinase 3 |
US7384942B2 (en) | 1999-12-17 | 2008-06-10 | Novartis Vaccines And Diagnostics, Inc. | Pyrazine based inhibitors of glycogen synthase kinase 3 |
US6995161B2 (en) | 2000-02-16 | 2006-02-07 | Neurogen Corporation | Substituted arylpyrazines |
US7202250B2 (en) | 2000-02-16 | 2007-04-10 | Neurogen Corporation | Substituted arylpyrazines |
WO2001087853A1 (fr) * | 2000-05-17 | 2001-11-22 | Universite Catholique De Louvain | Derives de pyrazine et d'imidazopyrazine comme antioxydants |
US7015227B2 (en) | 2002-06-21 | 2006-03-21 | Cgi Pharmaceuticals, Inc. | Certain amino-substituted monocycles as kinase modulators |
US7179807B2 (en) | 2002-08-20 | 2007-02-20 | Neurogen Corporation | 5-substituted-2-arylpyrazines |
Also Published As
Publication number | Publication date |
---|---|
JP2001524076A (ja) | 2001-11-27 |
BE1011077A3 (fr) | 1999-04-06 |
US6376498B1 (en) | 2002-04-23 |
CA2293359A1 (fr) | 1998-10-08 |
EP0975346A1 (fr) | 2000-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2132507C (fr) | Procede pour modifier la pousse des poils et/ou des cheveux et compositions utilisables a cet effet | |
FR2754713A1 (fr) | Utilisation de complexes pour la preparation de compositions pour le traitement des peaux sensibles, procede de preparation et compositions hypoallergeniques | |
FR2657526A1 (fr) | Utilisation d'un phosphate d'alpha-tocopherol, ou de l'un de ses derives, pour la preparation de compositions cosmetiques, dermatologiques, ou pharmaceutiques; compositions ainsi obtenues. | |
EP1035846B1 (fr) | Agnim comme agents anti-inflammatoires dans les tissus superficiels des mammiferes | |
EP1750695B1 (fr) | Utilisation d"alkyle furannes pour la preparation d'un medicament destine au traitement de l"obesite et pour le traitement cosmetique de la surcharge ponderale | |
FR2735979A1 (fr) | Utilisation comme substances therapeutiquement actives ou produits cosmetiques des sophorolipides, en particulier pour le traitement de la peau | |
FR2822381A1 (fr) | Extrait de cucumis melo enrobe et/ou microencapsule dans un agent liposoluble a base de matiere grasse | |
EP0796238B1 (fr) | Procede de stabilisation des acides gras poly-insatures et utilisation de ces produits stabilises en therapeutique et en cosmetologie | |
EP1765323B1 (fr) | Utilisation d'alkyle furannes pour la preparation d'un medicament destine au traitement du diabete | |
WO1996002488A9 (fr) | Procede de stabilisation des acides gras poly-insatures et utilisation de ces produits stabilises en therapeutique et en cosmetologie | |
EP3478368A1 (fr) | Composition pour lutter contre les signes du vieillissement de la peau et des phaneres | |
BE1011077A3 (fr) | Composition pharmaceutique, cosmetique et/ou alimentaire aux proprietes anti-oxydantes. | |
FR2926220A1 (fr) | Utilisation cosmetique d'un extrait de la plante pancratium maritimum comme agent cosmetique antioxydant et/ou inhibiteur de la melanogenese | |
CA2697125A1 (fr) | Utilisation d'au moins un derive oxime de la cholest-4-en-3-one comme antioxydants | |
EP1753391B1 (fr) | Utilisation d'alkyle furannes pour le traitement cosmetique de la cellulite | |
EP0197856B1 (fr) | Composition pour bains à base de psoralène dans le traitement du psoriasis | |
WO2009044011A2 (fr) | Utilisation d'au moins un dérivé oxime du 3,5-seco-4-nor-cholestane comme antioxydants | |
EP2254567B1 (fr) | N-acetyl-taurinate de zinc pour son utilisation dans une méthode de prévention et/ou de traitement des maladies avec accumulation de lipofuscine | |
FR2888509A1 (fr) | Extraits de ginkgo biloba | |
WO2009047618A1 (fr) | Compositions cosmétiques et/ou dermatologiques et leur utilisation pour la dépigmentation | |
FR2741533A1 (fr) | Procede de stabilisation des acides gras polyinsatures et utilisation de ces produits stabilises en cosmetologie | |
FR2747308A1 (fr) | Association de margousier, de (-) hydroxycitrate et de ceramides et compositions les renfermant | |
WO1996028160A1 (fr) | Composition pharmaceutique, cosmetique et/ou alimentaire aux prorpietes anti-oxydantes | |
WO1991000726A1 (fr) | UTILISATION D'AMPc OU SES DERIVES POUR LA PREPARATION DE COMPOSITIONS COSMETIQUE OU PHARMACEUTIQUE | |
EP1523321A1 (fr) | Utilisation d'extraits de ginkgo biloba pour favoriser la masse musculaire au detriment de la masse graisseuse |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2293359 Country of ref document: CA Kind code of ref document: A Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 1998 541001 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998913456 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1998913456 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09402099 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998913456 Country of ref document: EP |